PLP2 was significantly up‐regulated in GBMs compared with low‐grade gliomas (Figure 1A, P < .001), as shown previously.21 To further determine whether PLP2 expression was associated with aggressive clinicopathological characteristics, PLP2 immunohistochemical (IHC) staining was performed on 72 paraffin‐embedded glioma tissue samples, including grade II (n = 16), III (n = 21) and IV (n = 35) brain tumour samples and normal brain tissue (n = 5) samples (Figure 1B). This evidence concerns the gene PLP2 and central nervous system cancer.